Primaquine

Administration

• Type: Anti-malarial, anti-PCP
• Dosage Forms:
• Routes of Administration: oral
• Common Trade Names:

Adult Dosing

• PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
• Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
• Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Pediatric Dosing

• Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
• Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Special Populations

• Pregnancy Rating: D
• Lactation risk: Infant risk cannot be ruled out
• Renal dosing:
• Hepatic dosing:

Contraindications

• Allergy to class/drug
• Concomitant use with other potentially hemolytic or myeloid suppressing drugs
• Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)

Adverse Reactions

Serious

• Hemolytic anemia, leukopenia
• Methemoglobinemia

Common

• Nausea, abdominal pain

Pharmacology

• Half-life: 4-7 hours
• Metabolism:
• Excretion:

Mechanism of Action

• Eliminates tissue infection, thus preventing erythrocytic forms of parasite

See Also

• Malaria